Most random gene expression signatures are significantly associated with breast cancer outcome, according to a research team at Université Libre de Bruxelles.

Ipsogen's board has voted in favor of the deal, and shareholders holding 61 percent of Ipsogen's stock have agreed to sell their shares to Qiagen.

Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.

Qiagen has entered into exclusive negotiations to acquire 47 percent of Ipsogen's stock. After the completion of that deal, Qiagen would move to acquire all remaining shares of the French cancer molecular diagnostic firm.

Sysmex will distribute certain Ipsogen products in Japan and submit Ipsogen products for the diagnosis and monitoring of BCR-ABL and JAK2 to Japanese health authorities.

Product Watch


Agilent's SureSelect XT Mouse All Exon kit; NanoString's nCounter Mouse miRNA Expression kit; Ipsogen's BCR-ABL Mbcr IS-MMR kits; ATCC's Universal Mycoplasma Detection kit.

New Releases


Ipsogen's BCR-ABL Mbcr

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.